{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"萌喵读文献-肿瘤学","title":"今日肿瘤学最高分文献 - 2025-01-14","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/dccc4e51\"></iframe>","width":"100%","height":180,"duration":4,"description":"欢迎收听今日医学前沿！在最新的癌症治疗综述中，一项系统性回顾和元分析显示，Trastuzumab deruxtecan（T-DXd）在HER2阳性乳腺癌患者中展现出显著的治疗效果，特别是在脑转移和脑膜疾病。研究涵盖了18项研究，786名患者，结果显示60.4%的客观反应率、94.4%的疾病控制率和79.3%的临床获益率，以及12个月无进展生存率和总生存率分别为64.7%和82.7%。这为HER2阳性乳腺癌患者的中枢神经系统转移提供了新的治疗希望。不要错过这一突破性进展，深入了解T-DXd如何改变HER2阳性乳腺癌治疗的未来！","thumbnail_url":"https://img.transistorcdn.com/3WX36CzvFOrNjlF7WfWjzS4HdcMIMmzMs2bmPS-ejLU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NDNm/MjQ1N2E5NjhjMzVj/NjM0ZTA3YzY2NDE2/ZmIyMi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}